Moteur de recherche d’entreprises européennes
Financement de l’UE (15 M €) : Signatures de l’oncomicrobiome intestinal (GOMS) associées à l’incidence, au pronostic et à la prédiction de la réponse au traitement du cancer. Hor01/01/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Signatures de l’oncomicrobiome intestinal (GOMS) associées à l’incidence, au pronostic et à la prédiction de la réponse au traitement du cancer.
Beyond the role the intestinal metagenome plays in regulating multiple physBeyond its role in regulating multiple physiological functions that impact health, the intestinal metagenome is implicated in cancer initiation, progression and responses to therapies, even for extraintestinal neoplasia. Hence, there is an urgent need to fully identify and functionally characterize minimalist commensal ecosystems relevant to cancer, with reliable and robust methods, to validate cancer-associated gut microbiome fingerprints of high clinical relevance, and to develop diagnosis tools that will become part of the oncological arsenal for the optimization and personalization of therapy. Based on retro-and pro-spective studies, with large discovery and validation cohorts enrolling >9,000 cancer patients across 10 countries, ancillary to ongoing innovative clinical trials or FDA/EMA approvals across 4 frequent cancer types, ONCOBIOME will pursue the following aims: 1/ identify and validate core or cancer-specific Gut OncoMicrobiome Signatures (GOMS) associated with cancer occurrence, prognosis, response to, or progression on, therapy (polychemotherapy, immune checkpoint inhibitors, dendritic cell vaccines) or adverse effects, 2/ decipher the functional relevance of these cancer-associated gut commensal ecosystems in the regulation of host metabolism, immunity and oncogenesis, 3/ integrate these GOMS with other oncology hallmarks (clinics, genomics, immunomics, metabolomics) 4/ design optimal companion tests, based on those integrated signatures to predict cancer occurrence and progression. With high carat interdisciplinary experts, ONCOBIOME expects to validate cancer or therapy-specific Gut OncoMicrobiome Signatures (GOMS) across breast, colorectal, melanoma and lung cancers adjusting for covariates, to unravel the mode of action of these GOMS in innovative platforms, thus lending support to the design of cancer preventive campaigns using well characterized pre-and pro-biotics.
| Algoe SA | 210 612 € |
| Centre Hospitalier DE L'Universitede Montreal | 0,00 € |
| CHARITE - UNIVERSITAETSMEDIZIN BERLIN | 0,00 € |
| Everimmune | 519 000 € |
| Fondazione Irccs Istituto Nazionale DEI Tumori | 223 750 € |
| GBG FORSCHUNGS GmbH | 619 313 € |
| Gustave Roussy Transfert | 0,00 € |
| Iigm Foundation | 887 936 € |
| Institut Gustave Roussy | 2 942 215 € |
| Institut National de la Sante et de la Recherche Medicale | 898 275 € |
| Karolinska Institutet | 2 801 954 € |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 434 967 € |
| Masarykova Univerzita | 842 296 € |
| Masarykuv Onkologicky Ustav | 0,00 € |
| PHILIPPS UNIVERSITAET MARBURG | 703 063 € |
| STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM | 946 651 € |
| STICHTING RADBOUD UNIVERSITEIT | 15 570,03 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 413 386 € |
| Unicancer | 431 979 € |
| Universita Degli Studi Di Torino | 0,00 € |
| Universita Degli Studi Di Trento | 1 603 119 € |
| UNIVERSITATSKLINIKUM ERLANGEN | 412 158 € |
| Veracyte | 88 309 € |
https://cordis.europa.eu/project/id/825410
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.